Salt Lake City, Utah
Cancer biologic therapy trials in Salt Lake City, UT
44 cancer biologic therapy studies are recruiting participants at sites in Salt Lake City as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Salt Lake City at a glance
- 44 studies are recruiting at a site in Salt Lake City.
- By phase: Early Phase 1 (1), Phase 1 (4), Phase 1/2 (5), Phase 2 (13), Phase 2/3 (1), Phase 3 (19), Observational (1).
- By sponsor: university, hospital or other (20), industry (16), government (8).
- By research area: Lymphoma (26), Lung Cancer (7), Melanoma (6), Breast Cancer (4), Prostate Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Salt Lake City
Basic details from each study's public record (the 30 most recently updated of 44). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Utah, Huntsman Cancer Institute ( Site 0056)
- Registry record
- NCT06841354 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Huntsman Cancer Institute/University of Utah · University of Utah Sugarhouse Health Center
- Registry record
- NCT06876714 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Lung cancer studies recruiting in Salt Lake City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Huntsman Cancer Institute ( Site 0042)
- Registry record
- NCT06312137 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- From 18 minutes
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT06031688 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT06116682 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT06616584 · updated
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Huntsman Cancer Institute, University of Utah
- Registry record
- NCT07222566 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Prostate cancer studies recruiting in Salt Lake City
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Utah Cancer Specialists
- Registry record
- NCT07164443 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Melanoma studies recruiting in Salt Lake City
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT05136196 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- Huntsman Cancer Institute, University of Utah
- Registry record
- NCT06743126 · updated
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT05896839 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Lymphoma studies recruiting in Salt Lake City
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT06337318 · updated
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Study site
- Huntsman Cancer Institute, University of Utah
- Registry record
- NCT07478848 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Primary Children's Hospital
- Registry record
- NCT06173518 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Primary Children's Hospital
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Huntsman Cancer Institute/University of Utah · Primary Children's Hospital
- Registry record
- NCT05675410 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Intermountain Healthcare
- Registry record
- NCT07188558 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT03150693 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT05976763 · updated
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Phase 1/2
- From 6 months, up to 25 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Intermountain - Primary Children's Hospital ( Site 1014)
- Registry record
- NCT06395103 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study sites
- Huntsman Cancer Institute, University of Utah · Intermountain Health LDS Hospital
- Registry record
- NCT06500273 · updated
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AIDS Malignancy Consortium
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT04139304 · updated
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT05890352 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Primary Children's Hospital
- Registry record
- NCT06124157 · updated
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Phase 1/2
- Ages 18 to 80
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- Huntsman Cancer Institute
- Registry record
- NCT05861050 · updated
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT05886036 · updated
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT07220187 · updated
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Estrella Immunopharma, Inc.
- Study site
- Intermountain Health, Canyons Region, LDS Hospital
- Registry record
- NCT06343311 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Ask about studies near Salt Lake City
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections